A Phase 4 interventional study of Eltrombopag (ELT) in Thrombocytopaenia, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing eltrombopag in Thrombocytopenia — 2 open to participants now, 3 under way, none of them phase 3. eltrombopag · Thrombocytopenia.
Among the 53 studies testing eltrombopag in Thrombocytopenia, this one is the 40th largest by enrollment, is one of 6 that started in 2013, is one of 3 in phase 4, and was the 39th registered.
484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.
Browse Thrombocytopenia studies →2 of the 53 studies testing eltrombopag in Thrombocytopenia are open now, in 2 countries. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 3–99
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 33 · Phase 3 13 · Phase 4 3
First in 2005; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 54 across 336 interventional studies indexed under Thrombocytopenia.
Median enrollment 40 across the 53 interventional studies. Of the 45 that completed or were terminated, 25 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 53 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
10 studies in Thrombocytopenia by Novartis: none open now, none under way, none of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 10 studies in Thrombocytopenia by Novartis, this one is one of 2 that started in 2013, is one of 2 in phase 4, and was the 7th registered.
Novartis’s Thrombocytopenia studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 53 studies testing eltrombopag in Thrombocytopenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 10 in Thrombocytopenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study was to provide continued treatment with eltrombopag for subjects who were participating in a Novartis-sponsored investigational study with eltrombopag (parent studies 114968/ASPIRE (NCT01440374), PMA112509 (NCT00903422), and TRA105325/EXTEND (NCT00351468), receiving clinical benefit without unacceptable toxicity and to collect long-term safety data.
This Phase IV, multicenter, non-randomized, open-label, uncontrolled, rollover study was designed to provide continued access to eltrombopag to eligible subjects. As this study was a rollover study, the subjects were enrolled into this study from the parent studies.
There were 3 cohorts in this study:
Cohort A: Adult subjects who have completed study treatment with eltrombopag during their participation in a parent study for MDS/AML (i.e., 114968/ASPIRE and PMA112509).
Cohort B: Adult subjects who have completed study treatment with eltrombopag during their participation in a parent study for ITP (i.e., TRA105325/EXTEND).
Cohort C: Pediatric subjects who have completed study treatment with eltrombopag during their participation in a parent study for ITP. Once a subject turned 18 years of age, they might remain in the study and follow the Cohort B procedures. No pediatric subjects were enrolled in this cohort/study.
The study consisted of a transition visit, study treatment visits, and a follow-up visit. Subjects in Cohort A and Cohort B completed the Transition visit assessments and then returned for their next schedule visit as per the Visit schedule. In the study treatment visit, subjects received a starting dose of eltrombopag at the same dose and administration that they were receiving at the time of their last study treatment visit in the parent study.
Safety was evaluated through physical examinations, clinical laboratory tests, and monitoring of adverse events. Additional safety assessments were done as per standard of care and/or when medically indicated.
Assessment of clinical benefit was performed throughout the study using local standard of care as determined by the Investigator to determine continued study participation and treatment with eltrombopag. Only subjects considered by the Investigator to be receiving clinical benefit without unacceptable toxicity may continue on study treatment. Once treatment with eltrombopag was permanently discontinued, the subject would attend the follow-up visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects in this cohort received eltrombopag (ELT) at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that were used in this cohort were from 50 to 300 mg once daily (OD) for subjects of non-East Asian heritage. The dose ranges for subjects of East Asian heritage (i.e., Japanese, Chinese, Taiwanese, Thai and Korean) were 25 to 150 mg. Dose adjustments (if required) were done depending on each subject's platelet counts.
Drug: Eltrombopag (ELT)
All subjects in this cohort received ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that were used in this cohort were from 12.5 to 75 mg. Dose adjustments (if required) were done depending on each subject's platelet counts.
Drug: Eltrombopag (ELT)
All subjects in this cohort received ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that were used in this cohort were from 12.5 to 75 mg. Dose adjustments (if required) were done depending on each subject's platelet counts.
Drug: Eltrombopag (ELT)
Subjects were dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets were white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS was a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet contained ELT olamine equivalent to 20 mg of ELT per gram of powder.
Also known as: SB-497115
Number of Participants With Adverse Events (AEs)
The distribution of adverse events was done via the analysis of frequencies for Adverse Events (AEs) and Serious Adverse Events (SAEs), through the monitoring of relevant clinical and laboratory safety parameters. Only descriptive analysis performed.
Time frame: From the time of transition visit until 30 days after last dose of study treatment, assessed up to approximately 100 months.
22 subjects were enrolled in 14 centers in 12 countries (Belgium, China, France, Greece, Hong Kong, Ireland, Korea, Republic of., Netherlands, Peru, Poland, Romania, Tunisia).
| Milestone | Cohort A (Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukemia (AML) Adult Subjects) | Cohort B (Idiopathic Thrombocytopenic Purpura (ITP) Adult Subjects) |
|---|---|---|
| Started | 8 | 14 |
| Completed | 3 | 13 |
| Not completed | 5 | 1 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
The distribution of adverse events was done via the analysis of frequencies for Adverse Events (AEs) and Serious Adverse Events (SAEs), through the monitoring of relevant clinical and laboratory safety parameters. Only descriptive analysis performed.
| Participants | Cohort A (Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukemia (AML) Adult Subjects) | Cohort B (Idiopathic Thrombocytopenic Purpura (ITP) Adult Subjects) |
|---|---|---|
| Adverse Events (AEs) | 7 | 12 |
| Serious Adverse Events (SAEs) | 6 | 7 |
Collected over From the time of transition visit until 30 days after last dose of study treatment, assessed up to approximately 100 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A (Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukemia (AML) Adult Subjects) | 3/8 (37.5%) | 6/8 (75%) | 7/8 (87.5%) |
| Cohort B (Idiopathic Thrombocytopenic Purpura (ITP) Adult Subjects) | 2/14 (14.3%) | 7/14 (50%) | 12/14 (85.7%) |
| All Subjects | 5/22 (22.7%) | 13/22 (59.1%) | 19/22 (86.4%) |
| Event | Cohort A (Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukemia (AML) Adult Subjects) | Cohort B (Idiopathic Thrombocytopenic Purpura (ITP) Adult Subjects) | All Subjects |
|---|---|---|---|
| SepsisInfections and infestations | 2/8 | 0/14 | 2/22 |
| Atrial fibrillationCardiac disorders | 1/8 | 0/14 | 1/22 |
| AscitesGastrointestinal disorders | 1/8 | 0/14 | 1/22 |
| Multiple organ dysfunction syndromeGeneral disorders | 1/8 | 0/14 | 1/22 |
| PyrexiaGeneral disorders | 1/8 | 0/14 | 1/22 |
| Cholecystitis acuteHepatobiliary disorders | 1/8 | 0/14 | 1/22 |
| PneumoniaInfections and infestations | 1/8 | 1/14 | 2/22 |
| Alanine aminotransferase increasedInvestigations | 1/8 | 0/14 | 1/22 |
| HypernatraemiaMetabolism and nutrition disorders | 1/8 | 0/14 | 1/22 |
| Subdural hygromaNervous system disorders | 1/8 | 0/14 | 1/22 |
| Event | Cohort A (Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukemia (AML) Adult Subjects) | Cohort B (Idiopathic Thrombocytopenic Purpura (ITP) Adult Subjects) | All Subjects |
|---|---|---|---|
| PyrexiaGeneral disorders | 4/8 | 3/14 | 7/22 |
| Oedema peripheralGeneral disorders | 3/8 | 1/14 | 4/22 |
| EosinophiliaBlood and lymphatic system disorders | 0/8 | 5/14 | 5/22 |
| Upper respiratory tract infectionInfections and infestations | 1/8 | 5/14 | 6/22 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/8 | 5/14 | 6/22 |
| HeadacheNervous system disorders | 1/8 | 5/14 | 6/22 |
| DiarrhoeaGastrointestinal disorders | 1/8 | 4/14 | 5/22 |
| HypertensionVascular disorders | 1/8 | 4/14 | 5/22 |
| AnaemiaBlood and lymphatic system disorders | 2/8 | 2/14 | 4/22 |
| FatigueGeneral disorders | 2/8 | 0/14 | 2/22 |
| Age, Continuous(Years) | Cohort A (Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukemia (AML) Adult Subjects) | Cohort B (Idiopathic Thrombocytopenic Purpura (ITP) Adult Subjects) | Total |
|---|---|---|---|
| Mean | 73.8 ± 7.57 | 59.5 ± 13.18 | 64.7 ± 13.26 |
| Sex: Female, Male(Participants) | Cohort A (Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukemia (AML) Adult Subjects) | Cohort B (Idiopathic Thrombocytopenic Purpura (ITP) Adult Subjects) | Total |
|---|---|---|---|
| Female | 3 | 12 | 15 |
| Male | 5 | 2 | 7 |
| Race/Ethnicity, Customized(Participants) | Cohort A (Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukemia (AML) Adult Subjects) | Cohort B (Idiopathic Thrombocytopenic Purpura (ITP) Adult Subjects) | Total |
|---|---|---|---|
| American Indian or Alaskan Native | 0 | 2 | 2 |
| Asian - East Asian Heritage | 1 | 5 | 6 |
| White - Arabic/North African Heritage | 0 | 6 | 6 |
| White - White/Caucasian/European Heritage | 7 | 1 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Oct 2013 to primary completion in Feb 2022, 100 months.
Results were first posted in Dec 2022, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag